COVID-19 research campaign moves from basic science to antiviral drug design

ORNL researchers have developed and tested novel small-molecule antivirals in an effort to design new drugs to treat COVID-19. The so called hybrid inhibitor molecules are made from repurposed drugs used to treat hepatitis C and the original coronavirus outbreak in the early 2000s. The experimental research results show the molecules are similarly as effective as some of the leading drugs on the market today.